REG - GENinCode PLC - Notice of Results

GenincodeAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5201Pa&default-theme=true

RNS Number : 5201P  GENinCode PLC  23 May 2024

GENinCode Plc

("GENinCode" or the "Company")

 

Notice of results

Analyst and investor briefing

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease and ovarian cancer, announces that
it will release its audited final results for the year ended 31 December 2023
on Monday, 3 June 2024.

 

 

Analyst briefing

A briefing open to equity research analysts will take place on Monday 3 June
2024 at 09.30am BST. To register and for more details please contact Walbrook
PR on genincode@walbrookpr.com (mailto:genincode@walbrookpr.com) .

 

Investor presentation

Matthew Walls, Chief Executive Officer, and Paul Foulger, Chief Financial
Officer, will provide a live presentation relating to the results via the
Investor Meet Company platform on Tuesday, 4 June at 2pm BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard until 9am
the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
GENinCode here
(https://www.investormeetcompany.com/genincode-plc/register-investor) .
Investors who already follow GENinCode on the Investor Meet Company platform
will automatically be invited.

 

For more information visit www.genincode.com (http://www.genincode.com)

 

Enquiries:

 

 GENinCode Plc                       www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Cavendish Capital Markets Limited   Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks / Harriet Ward (Corporate Broking)
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                   Tel: 020 7933 8780 or genincode@walbrookpr.com

                                                                     (mailto:genincode@walbrookpr.com)
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

 

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease and ovarian cancer. Cardiovascular disease is the
leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventive care and treatment strategies. GENinCode invitro-diagnostic
molecular tests combine clinical algorithms and AI bioinformatics to advance
patient risk assessment to prevent the onset of cardiovascular disease and
ovarian cancer.

 

About Cardiovascular Disease (CVD):

 

CVD is the leading cause of death globally, taking an estimated 17.9 million
lives each year. CVD is a group of disorders of the heart and blood vessels
and include coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths are due to
heart attacks and strokes, and one third of these deaths occur prematurely in
people under 70 years of age.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas with the NHS 10 Year Plan identifying
CVD as the single biggest area where the NHS can save lives over the next 10
years. CVD is largely preventable, through lifestyle changes and a combination
of public health and NHS action on smoking and tobacco addiction, obesity,
tackling alcohol misuse and food reformulation.

 

Early detection and treatment of CVD can help patients live longer, healthier
lives. Too many people are still living with undetected, high-risk conditions
such as high blood pressure, raised cholesterol, and atrial fibrillation (AF).
The NHS 10 Year Plan is working towards people knowing and managing risks
around their 'ABC' (AF, Blood pressure and Cholesterol).

 

About Ovarian Cancer (OC) and the ROCA test:

OC occurs when abnormal cells in the ovaries or fallopian tubes grow and
multiply out of control. Ovaries are part of the female reproductive system
and are responsible for making eggs during a female's reproductive years.

OC affects women and people assigned female at birth. It accounts for 1% of
all new cancer cases and the lifetime risk of developing OC is approximately 1
in 78. OC is slightly more common in white populations than in people who are
Black, Hispanic or Asian, while people who inherit a BRCA gene mutation are
consider high risk of developing the disease. BRCA gene mutations occur in
0.3% of the population but is more common in individuals of Ashkenazi Jewish
or Greenlander descent. Preventative surgery (removal of both ovaries and
fallopian tubes) is recommended for BRCA carriers.

Diagnosis of OC typically occurs late stage due to the presentation of vague
symptoms that are often confused with other more common conditions. As a
result, treatment is intense and long-term survival is poor. Despite years of
research, experts have struggled to develop an effective OC surveillance test
that can detect the disease earlier.

The Risk of Ovarian Cancer Algorithm (ROCA) Test is a globally leading OC
surveillance test, proven to detect OC cancer before symptoms present and at
an earlier stage. The test is intended for women over 35 with a mutation in
the BRCA1 or BRCA2 gene and who wish to defer preventative surgery. The ROCA
test has recently received National Institute for Care and Health Excellence
(NICE) guideline recommendation for OC surveillance.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORATMITMTJTBPI